CRISPR Gene Editing Newsletter
Issue #3September 22, 20257 studies

CRISPR fixes rare vascular disease in mice + new gene editing tools get safer

CRISPR fixes rare vascular disease in mice + new gene editing tools get safer

Monday, Monday, September 22nd CRISPR Gene Editing Newsletter Issue #3

This week brought major breakthroughs in making gene editing both more powerful and safer. From fixing a deadly childhood vascular disease to creating controllable editing tools, researchers are turning CRISPR from a promising lab technique into precision medicine.

🧬 Custom CRISPR saves mice from deadly childhood vascular disease

Scientists engineered a bespoke CRISPR system to treat multisystemic smooth muscle dysfunction syndrome (MSMDS), a rare genetic disease that causes strokes, aortic dissection, and death in children. Here's what made this breakthrough special:

  • They custom-built a CRISPR editor specifically for the most common MSMDS mutation (R179H), then screened dozens of configurations to minimize harmful side effects

  • When delivered to MSMDS mice via a smooth muscle-targeting virus, the treatment substantially prolonged survival and rescued disease symptoms across the vasculature, aorta, and brain

  • This represents a shift from one-size-fits-all gene editing to mutation-specific precision tools

Why this matters: This study shows we can now engineer CRISPR systems tailored to individual genetic mutations, potentially opening treatment paths for thousands of rare diseases that affect specific cell types.

🥇 Top 1% journal 🔗 Nature Biomedical Engineering 🗓️ Sep 11

Key Findings

🎯 New method maps how gene edits change chromosome accessibility

Researchers developed TDAC-seq, which uses DNA-eating enzymes to track how CRISPR edits affect chromosome structure at single-molecule resolution. They tested it on 947 genetic variants linked to blood cancer risk in a single experiment, showing how each edit changed DNA accessibility patterns.

💡 We can now see exactly how gene edits reshape chromosome structure, making CRISPR design more predictable.
🏆 Top 0.1% journal 🔗 Nature Methods 🗓️ Sep 11

🔬 Safer gene editing with controllable 'split' CRISPR

Scientists split a key CRISPR component (TadA-8e) into two pieces that only work when brought together by a drug signal. This split system maintained comparable editing efficiency to regular CRISPR while reducing both DNA and RNA off-target effects - the unwanted edits that raise safety concerns.

💡 Gene editing can now be turned on and off like a light switch, making it safer for clinical use.
🥉 Top 5% journal 🔗 Molecular Therapy Nucleic Acids 🗓️ Sep 8

🧪 Engineered B cells become living drug factories for hemophilia

Researchers created BE-101, an autologous treatment where patients' own B cells are engineered to produce clotting factor IX. The modified cells reached steady production within 2 weeks and maintained it for over 184 days in mice, with the ability to redose for proportional increases in drug levels.

💡 Your own immune cells can be reprogrammed into personalized drug factories that work for months.
🥈 Top 2% journal 🔗 Molecular Therapy 🗓️ Sep 7

💡 CAR-T cells get safer with RNA silencing instead of gene cutting

Instead of using CRISPR to cut genes in cancer-fighting CAR-T cells, researchers used targeted microRNAs to silence unwanted genes. These 'silenced' CAR-T cells showed equal or better tumor control than gene-edited versions, with higher persistence and superior prevention of cancer spread.

💡 Gene silencing may be safer than gene cutting for engineering cancer immunotherapies.
🥉 Top 5% journal 🔗 Frontiers in Immunology 🗓️ Sep 8

🔬 Off-the-shelf CAR-T cells target hard-to-treat cancers

Scientists created universal CAR-T cells by knocking out T-cell receptors, allowing them to target B7H6-expressing cancers like acute myeloid leukemia and melanoma without causing immune rejection. These cells showed superior anti-tumor activity compared to regular CAR-T cells in mouse models.

💡 Universal cancer-fighting cells could eliminate the need for patient-specific manufacturing.

🧬 Pancreatic cancer's mechanical weakness revealed

A CRISPR screen identified DDX3X as a key driver of pancreatic cancer that works by disrupting cellular mechanics. The protein affects how cancer cells generate traction forces through the DDX3X-TLE2-MYL9 pathway, suggesting new therapeutic targets beyond traditional biochemical approaches.

💡 Targeting cancer's mechanical properties, not just its chemistry, could unlock new treatments.
🥈 Top 2% journal 🔗 Science Advances 🗓️ Sep 12

Implications

Gene editing is rapidly evolving from a crude molecular scissors into a precision toolkit with safety controls, custom designs, and alternatives to DNA cutting. These advances are bringing us closer to treating rare diseases, making cancer immunotherapy safer and more accessible, and understanding biology at unprecedented resolution.

Studies in this issue

Primary sources used for this newsletter.

  1. Using a custom gene editor to treat a serious blood vessel disease in mice
    main storyNature biomedical engineering2025-09-11PMID 40935887
  2. Gene-Edited Immune Cells Targeting NKp30 Show Stronger Anti-Tumor Response to Leukemia and Melanoma with B7H6
    key findingInternational journal of molecular sciences2025-09-13PMID 40943160
  3. A gene-engineered B cell treatment that maintains steady active factor IX levels for hemophilia B
    key findingMolecular therapy : the journal of the American Society of Gene Therapy2025-09-07PMID 40914806
  4. Combining CRISPR scanning with targeted profiling of open DNA regions using a double-stranded DNA editing enzyme
    key findingNature methods2025-09-11PMID 40935921
  5. RNA-binding protein DDX3X may promote pancreatic cancer growth through the TLE2-MYL9 pathway
    key findingScience advances2025-09-12PMID 40938994
  6. A set of precise and adjustable DNA base editors using split TadA-8e enzyme
    key findingMolecular therapy. Nucleic acids2025-09-08PMID 40917891
  7. Using microRNA to control multiple genes in CAR T cell therapy
    key findingFrontiers in immunology2025-09-08PMID 40918142

Continue reading

All CRISPR Gene Editing issues